Oxford Biomedica names chief development officer
This article was originally published in Scrip
Oxford BioMedica, a gene and cell therapy company, has named its non-executive director Dr Paul Blake to its executive management team as chief development officer – effective 1 September 2014. Dr Blake joined the board of Oxford BioMedica in January 2010 and will retain his seat alongside his new position. Most recently, Dr Blake was senior vice-president and chief medical officer of Æterna Zentaris, a global biopharmaceutical company focused on oncology and endocrine therapy.